$83.51 0.00 (%) Biomarin Pharmaceutical Inc - NASDAQ

Dec. 8, 2016 | 04:00 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Biotechs Unhinged By Tough Pricing Talk

    TalkMarkets | Dec. 8, 2016 | 23:04PM EST
  2. Rayno Biobeat #4: Sector Shift Underway But What’s Next For Biotech?

    TalkMarkets | Nov. 23, 2016 | 00:13AM EST
  3. Stock Exchange: Is Technical Analysis Effective Post-Election?

    TalkMarkets | Nov. 10, 2016 | 22:46PM EST
  4. Biogen Upgraded To Overweight From Neutral At Piper Jaffray

    TalkMarkets | Nov. 7, 2016 | 08:08AM EST
  5. Weighing the Week Ahead: Time for Some Clarity?

    TalkMarkets | Nov. 6, 2016 | 01:03AM EST
  6. Stock Exchange: Contrarian Pre-Election Trade Ideas In Chips, Biotech, Trucking, And Energy

    TalkMarkets | Nov. 4, 2016 | 08:53AM EST
  7. Contrarian Pre-Election Trade Ideas In Chips, Biotech, Trucking, And Energy

    TalkMarkets | Nov. 4, 2016 | 08:53AM EST
  8. Seattle Genetics (SGEN) Loss Narrower Than Expected In Q3

    TalkMarkets | Oct. 29, 2016 | 19:13PM EST
  9. J&J Outshines in Q3 Earnings on Strong Pharma Sales

    TalkMarkets | Oct. 18, 2016 | 11:01AM EST
  10. Swing Trading Watch List - October 11, 2016

    TalkMarkets | Oct. 11, 2016 | 22:19PM EST
  11. Sarepta Stock Slides As FDA Sends Another Bad Signal On DMD

    IBD | Jul. 14, 2016 | 10:13AM EST
  12. Roche Holdings Definitely Not a Lumbering Giant

    GuruFocus | Jul. 11, 2016 | 12:24PM EST
  13. The FDA Just Crushed Sarepta Therapeutics' Hopes Of Releasing A Muscular Dystrophy Drug

    Benzinga | Jan. 21, 2016 | 11:23AM EST
  14. Sarepta Plummets As FDA Slams Muscular Dystrophy Drug

    IBD | Jan. 15, 2016 | 12:53PM EST
  15. BioMarin Muscular Dystrophy Drug Rejected By FDA

    IBD | Jan. 14, 2016 | 12:29PM EST
  16. BioMarin Announces Interim Analysis of INSPIRE Clinical Trial in Pompe Disease, Encouraged By Positive Trends In Trial

    Benzinga | Jan. 11, 2016 | 11:35AM EST
  17. BioMarin, Intercept hit by FDA

    IBD | Dec. 18, 2015 | 18:47PM EST
  18. BioMarin, Intercept Pharma Drugs Face FDA Delays

    IBD | Dec. 18, 2015 | 12:13PM EST
  19. BioMarin Announces That FDA Has Advised it Will Not Take Action on the Kyndrisa™ (drisapersen) New Drug Application by the PDUFA Date

    Benzinga | Dec. 18, 2015 | 08:30AM EST
  20. Pharmaceutical Stocks Hold Prominent Positions in Kyle Bass' 3rd-Quarter Activity

    GuruFocus | Nov. 27, 2015 | 16:10PM EST
  21. FDA Panel Seen As Bad For BioMarin, Good For Sarepta

    IBD | Nov. 25, 2015 | 14:34PM EST
  22. FDA Advisory Committee Discusses Clinical Data Package for BioMarin's Kyndrisa for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

    Benzinga | Nov. 24, 2015 | 19:36PM EST
  23. BioMarin Drug's Future In Doubt After FDA Panel Vote

    IBD | Nov. 24, 2015 | 18:41PM EST
  24. BIOMARIN PHARMA

    IBD | Nov. 24, 2015 | 18:33PM EST
  25. KaloBios, Valeant Lead Week's 5 Top Drug Stock Gainers

    IBD | Nov. 21, 2015 | 08:15AM EST
  26. Here's Why Sarepta Is Skyrocketing While BioMarin Is Falling

    Benzinga | Nov. 20, 2015 | 10:19AM EST
  27. Morning Market Losers

    Benzinga | Nov. 20, 2015 | 10:06AM EST
  28. Benzinga's Top #PreMarket Losers

    Benzinga | Nov. 20, 2015 | 08:17AM EST
  29. Goldman Sachs' Top 4 Smid-Cap Biotech Picks

    IBD | Nov. 18, 2015 | 15:36PM EST
  30. Benzinga's Top Initiations

    Benzinga | Nov. 18, 2015 | 09:34AM EST
  31. Biotech ETFs: Buy, Buy, Buy?

    Benzinga | Oct. 27, 2015 | 06:19AM EST
  32. Hurricane Hillary Shifts Left, Slamming More Stocks

    IBD | Oct. 22, 2015 | 14:52PM EST
  33. PTC Stock Seesaws On Muscular Dystrophy Drug Data

    IBD | Oct. 15, 2015 | 17:54PM EST
  34. BioMarin's Initial 6-Month Data From Phase 2 Study of Vosoritide (BMN 111) in Children With Achondroplasia Presented at the American Society for Bone and Mineral Research Annual 2015 Meeting

    Benzinga | Oct. 12, 2015 | 15:30PM EST
  35. Sarepta Stock Soars On New Muscular-Dystrophy Data

    IBD | Oct. 1, 2015 | 10:19AM EST
  36. BioMarin to Acquire Rights to Phenylketonuria (PKU) Franchise From Merck Serono

    Benzinga | Oct. 1, 2015 | 03:23AM EST
  37. Wednesday's After-Hours Movers: PBF Energy, BioMarin Pharmaceutical And More

    Benzinga | Sep. 30, 2015 | 15:42PM EST
  38. Stocks Rally, Will Gains Hold? Biotechs Try Second Rebound

    IBD | Sep. 30, 2015 | 09:43AM EST
  39. Benzinga's Top #PreMarket Losers

    Benzinga | Sep. 30, 2015 | 07:31AM EST
  40. Amgen And Biogen Lead Short Interest Surge In Biotechs

    Benzinga | Sep. 14, 2015 | 15:01PM EST
  41. BioMarin Announces Two Oral and 19 Poster Presentations at the Society for the Study of Inborn Errors of Metabolism 2015 Annual Meeting

    Benzinga | Aug. 31, 2015 | 07:33AM EST
  42. Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to ...

    GuruFocus | Aug. 24, 2015 | 23:02PM EST
  43. Benzinga's M&A Chatter for Monday August 24, 2015

    Benzinga | Aug. 24, 2015 | 17:44PM EST
  44. Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib, a Potent PARP Inhibitor, From BioMarin

    Benzinga | Aug. 24, 2015 | 06:00AM EST
  45. BioMarin Receives Rare Pediatric Disease Designation From FDA for Drisapersen for the Potential Treatment of Duchenne Muscular Dystrophy

    Benzinga | Aug. 19, 2015 | 15:08PM EST
  46. BioMarin Gets Price Target Hike On Pipeline Strength

    IBD | Jul. 8, 2015 | 11:12AM EST
  47. 2 DMD drugs make progress

    IBD | Jun. 29, 2015 | 17:45PM EST
  48. BioMarin, Sarepta Muscular Dystrophy Drugs Progress

    IBD | Jun. 29, 2015 | 09:18AM EST
  49. Baird Downgrades BioMarin Pharmaceutical To Neutral

    Benzinga | Jun. 19, 2015 | 09:31AM EST
  50. Benzinga's Volume Movers

    Benzinga | Jun. 19, 2015 | 09:31AM EST
Trading Center